吴涵芝,尹艳伟,叶新和,杨承健

• 1:无锡市第二人民医院心血管内科南京医科大学无锡临床医学院

摘要(Abstract)：

急性冠状动脉综合征发病率高且预后较差，及时行经皮冠状动脉介入治疗开通罪犯血管是目前救治的关键。术中可发现许多患者合并有多支血管病变，且部分非罪犯病变会快速进展导致不良事件的发生。因此对非罪犯病变的评估和适当干预成为目前研究的热点。相较于传统的冠状动脉造影，冠状动脉功能学检查及影像学技术为进一步评估病变的血流储备能力、斑块特点及是否需要血运重建等方面提供了有力帮助。近年来临床研究发现，完全血运重建相较于仅处理罪犯血管可以改善患者的临床结局。本文对如何管理非罪犯病变进行综述。

关键词(KeyWords)： 急性冠状动脉综合征;多支血管病变;功能学检查;腔内影像学技术;完全血运重建

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 吴涵芝,尹艳伟,叶新和,杨承健

参考文献(References)：

• [1] Bergmark BA,Mathenge N,Merlini PA,et al. Acute coronary syndromes[J]. Lancet,2022,399(10332):1347-1358.DOI:10.1016/s0140-6736(21)02391-6.
• [2] Collet JP,Thiele H,Barbato E,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J].Eur Heart J,2021,42(14):1289-1367. DOI:10.1093/eurheartj/ehaa575.
• [3] Bhatt DL,Lopes RD,Harrington RA. Diagnosis and treatment of acute coronary syndromes:a review[J]. JAMA,2022,327(7):662-675. DOI:10.1001/jama.2022.0358.
• [4] Ibanez B,James S,Agewall S,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)[J]. Eur Heart J,2018,39(2):119-177. DOI:10.1093/eurheartj/ehx393.
• [5] Fearon WF. Assessing nonculprit coronary disease in ST-segment elevation myocardial infarction with physiological testing[J].JAMA Cardiol,2019,4(8):745-746. DOI:10.1001/jamacardio.2019.2217.
• [6] Varenhorst C,Hasvold P,Johansson S,et al. Culprit and nonculprit recurrent ischemic events in patients with myocardial infarction:data from SWEDEHEART(Swedish Web System for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies)[J]. J Am Heart Assoc,2018,7(1):e007174. DOI:10.1161/jaha.117.007174.
• [7] Lawton JS,Tamis-Holland JE,Bangalore S,et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization:a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines[J].Circulation,2022,145(3):e18-e114. DOI:10.1161/CIR.0000000000001038.
• [8] Berry C,Layland J,Sood A,et al. Fractional fiow reserve versus angiography in guiding management to optimize outcomes in non-STelevation myocardial infarction(FAMOUS-NSTEMI):rationale and design of a randomized controlled clinical trial[J]. Am Heart J,2013,166(4):662-668. DOI:10.1016/j.ahj.2013.07.011.
• [9] De Bruyne B,Pijls NH,Kalesan B,et al. Fractional fiow reserveguided PCI versus medical therapy in stable coronary disease[J].N Engl J Med,2012,367(11):991-1001. DOI:10.1056/NEJMoa1205361.
• [10] Engstr?m T,Kelb?k H,Helqvist S,et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease(DANAMI-3—PRIMULTI):an openlabel,randomised controlled trial[J].Lancet,2015,386(9994):665-671. DOI:10.1016/s0140-6736(15)60648-1.
• [11] Pijls NH,van Schaardenburgh P,Manoharan G,et al. Percutaneous coronary intervention of functionally nonsignificant stenosis:5-year follow-up of the DEFER study[J]. J Am Coll Cardiol,2007,49(21):2105-2111. DOI:10.1016/j.jacc.2007.01.087.
• [12] Smits PC,Abdel-Wahab M,Neumann FJ,et al. Fractional fiow reserve-guided multivessel angioplasty in myocardial infarction[J].N Engl J Med,2017,376(13):1234-1244. DOI:10.1056/NEJMoa1701067.
• [13] van Nunen LX,Zimmermann FM,Tonino PAL,et al. Fractional fiow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease(FAME):5-year follow-up of a randomised controlled trial[J]. Lancet,2015,386(10006):1853-1860. DOI:10.1016/s0140-6736(15)00057-4.
• [14] Ntalianis A,Sels JW,Davidavicius G,et al. Fractional fiow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction[J]. JACC Cardiovasc Interv,2010,3(12):1274-1281. DOI:10.1016/j.jcin.2010.08.025.
• [15] Martins JL,Afreixo V,Santos J,et al. Fractional fiow reserveguided strategy in acute coronary syndrome. A systematic review and meta-analysis[J]. Arq Bras Cardiol,2018,111(4):542-550. DOI:10.5935/abc.20180170.
• [16] Cerrato E,Mejía-Rentería H,Dehbi HM,et al. Revascularization deferral of nonculprit stenoses on the basis of fractional flow reserve:1-year outcomes of 8,579 patients[J]. JACC Cardiovascular Interventions,2020,13(16):1894-1903.DOI:10.1016/j.jcin.2020.05.024.
• [17] Ross R. The pathogenesis of atherosclerosis--an update[J].N Engl J Med,1986,314(8):488-500. DOI:10.1056/nejm198602203140806.
• [18] Burke AP,Farb A,Malcom GT,et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly[J]. N Engl J Med,1997,336(18):1276-1282.DOI:10.1056/nejm199705013361802.
• [19] Virmani R,Burke AP,Farb A,et al. Pathology of the vulnerable plaque[J]. J Am Coll Cardiol,2006,47(8 Suppl):C13-C18. DOI:10.1016/j.jacc.2005.10.065.
• [20] Little CD,Colchester RJ,Noimark S,et al. Optically generated ultrasound for intracoronary imaging[J]. Front Cardiovasc Med,2020,7:525530. DOI:10.3389/fcvm.2020.525530.
• [21] Hong YJ,Ahn Y,Jeong MH. Role of intravascular ultrasound in patients with acute myocardial infarction[J]. Korean Circ J,2015,45(4):259-265. DOI:10.4070/kcj.2015.45.4.259.
• [22] Maehara A,Cristea E,Mintz GS,et al. Definitions and methodology for the grayscale and radiofrequency intravascular ultrasound and coronary angiographic analyses[J]. JACC Cardiovasc Imaging,2012,5(3 Suppl):S1-S9. DOI:10.1016/j.jcmg.2011.11.019.
• [23] Stone GW,Maehara A,Lansky AJ,et al. A prospective naturalhistory study of coronary atherosclerosis[J]. N Engl J Med,2011,364(3):226-235. DOI:10.1056/NEJMoa1002358.
• [24]谢剑昶，黄进宇.基于血管内超声斑块组织学检测方法的历史及现状[J].中国介入心脏病学杂志，2018,26(11):645-648. DOI:10.3969/j.issn.1004-8812.2018.11.010.
• [25] Erlinge D,Maehara A,Ben-Yehuda O,et al. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound(PROSPECTⅡ)：a prospective natural history study[J]. Lancet,2021,397(10278):985-995. DOI:10.1016/s0140-6736(21)00249-x.
• [26] Fujii K,Kubo T,Otake H,et al. Expert consensus statement for quantitative measurement and morphological assessment of optical coherence tomography:update 2022[J]. Cardiovasc Interv Ther,2022,37(2):248-254. DOI:10.1007/s12928-022-00845-3.
• [27] Lv R,Maehara A,Matsumura M,et al. Using optical coherence tomography and intravascular ultrasound imaging to quantify coronary plaque cap thickness and vulnerability:a pilot study[J]. Biomed Eng Online,2020,19(1):90. DOI:10.1186/s12938-020-00832-w.
• [28] Gurgoglione FL,Denegri A,Russo M,et al. Intracoronary imaging of coronary atherosclerotic plaque:from assessment of pathophysiological mechanisms to therapeutic implication[J]. Int J Mol Sci,2023,24(6):5155. DOI:10.3390/ijms24065155.
• [29] Prati F,Romagnoli E,Gatto L,et al. Relationship between coronary plaque morphology of the left anterior descending artery and12 months clinical outcome:the CLIMA study[J]. Eur Heart J,2020,41(3):383-391. DOI:10.1093/eurheartj/ehz520.
• [30] Araki M,Soeda T,Kim HO,et al. Spatial distribution of vulnerable plaques:comprehensive in vivo coronary plaque mapping[J]. JACC Cardiovasc Imaging,2020,13(9):1989-1999. DOI:10.1016/j.jcmg.2020.01.013.
• [31] Kedhi E,Berta B,Roleder T,et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional fiow reserve:the COMBINE OCT-FFR trial[J]. Eur Heart J,2021,42(45):4671-4679. DOI:10.1093/eurheartj/ehab433.
• [32] Emori H,Kubo T,Shiono Y,et al. Comparison of optical fiow ratio and fractional fiow ratio in stent-treated arteries immediately after percutaneous coronary intervention[J]. Circ J,2020,84(12):2253-2258. DOI:10.1253/circj.CJ-20-0661.
• [33]中国医师协会放射医师分会.冠状动脉CT血管成像斑块分析和应用中国专家建议[J].中华放射学杂志，2022,56(6):595-607. DOI:10.3760/cma.j.cn112149-20211129-01055.
• [34] Ferencik M,Mayrhofer T,Bittner DO,et al. Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain:a secondary analysis of the PROMISE randomized clinical trial[J]. JAMA Cardiol,2018,3(2):144-152. DOI:10.1001/jamacardio.2017.4973.
• [35] Williams MC,Moss AJ,Dweck M,et al. Coronary artery plaque characteristics associated with adverse outcomes in the SCOT-HEART study[J]. J Am Coll Cardiol,2019,73(3):291-301. DOI:10.1016/j.jacc.2018.10.066.
• [36] Yu M,Li W,Lu Z,et al. Quantitative baseline CT plaque characterization of unrevascularized non-culprit intermediate coronary stenosis predicts lesion volume progression and longterm prognosis:a serial CT follow-up study[J]. Int J Cardiol,2018,264:181-186. DOI:10.1016/j.ijcard.2018.03.021.
• [37] Tan Y,Zhou J,Zhou Y,et al. Characteristics detected on computed tomography angiography predict coronary artery plaque progression in non-culprit lesions[J]. Korean J Radiol,2017,18(3):487-497. DOI:10.3348/kjr.2017.18.3.487.
• [38] Taylor CA,Fonte TA,Min JK. Computational fiuid dynamics applied to cardiac computed tomography for noninvasive quantification of fractional fiow reserve:scientific basis[J]. J Am Coll Cardiol,2013,61(22):2233-2241. DOI:10.1016/j.jacc.2012.11.083.
• [39] Koo BK,Erglis A,Doh JH,et al. Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional fiow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW(Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve)study[J]. J Am Coll Cardiol,2011,58(19):1989-1997. DOI:10.1016/j.jacc.2011.06.066.
• [40] Min JK,Leipsic J,Pencina MJ,et al. Diagnostic accuracy of fractional fiow reserve from anatomic CT angiography[J]. JAMA,2012,308(12):1237-1245. DOI:10.1001/2012.jama.11274.
• [41] N?rgaard BL,Leipsic J,Gaur S,et al. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease:the NXT trial(Analysis of Coronary Blood Flow Using CT Angiography:Next Steps)[J]. J Am Coll Cardiol,2014,63(12):1145-1155. DOI:10.1016/j.jacc.2013.11.043.
• [42] Cai JM,Hatsukami TS,Ferguson MS,et al. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging[J]. Circulation,2002,106(11):1368-1373. DOI:10.1161/01.cir.0000028591.44554.f9.
• [43] Károlyi M,Seifarth H,Liew G,et al. Classification of coronary atherosclerotic plaques ex vivo with T1,T2,and ultrashort echo time CMR[J]. JACC Cardiovasc Imaging,2013,6(4):466-474. DOI:10.1016/j.jcmg.2012.09.015.
• [44] Beijnink CWH,van der Hoeven NW,Konijnenberg LSF,et al. Cardiac MRI to visualize myocardial damage after ST-Segment elevation myocardial infarction:a review of its histologic validation[J].Radiology,2021,301(1):4-18. DOI:10.1148/radiol.2021204265.
• [45] de Waha S,Desch S,Eitel I,et al. Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction:a comparison with traditional prognostic markers[J]. Eur Heart J,2010,31(21):2660-2668. DOI:10.1093/eurheartj/ehq247.
• [46] Everaars H,van der Hoeven NW,Janssens GN,et al. Cardiac magnetic resonance for evaluating nonculprit lesions after myocardial infarction:comparison with fractional flow reserve[J]. JACC Cardiovasc Imaging,2020,13(3):715-728. DOI:10.1016/j.jcmg.2019.07.019.
• [47] Cri?an G,Moldovean-Cioroianu NS,Timaru DG,et al.Radiopharmaceuticals for PET and SPECT imaging:a literature review over the last decade[J]. Int J Mol Sci,2022,23(9):5023. DOI:10.3390/ijms23095023.
• [48] Tawakol A,Migrino RQ,Bashian GG,et al. In vivo18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients[J]. J Am Coll Cardiol,2006,48(9):1818-1824.DOI:10.1016/j.jacc.2006.05.076.
• [49] Joshi NV,Vesey AT,Williams MC,et al. 18F-fiuoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques:a prospective clinical trial[J]. Lancet,2014,383(9918):705-713. DOI:10.1016/s0140-6736(13)61754-7.
• [50] Naghavi M,Libby P,Falk E,et al. From vulnerable plaque to vulnerable patient:a call for new definitions and risk assessment strategies:PartⅠ[J]. Circulation,2003,108(14):1664-1672. DOI:10.1161/01.CIR.0000087480.94275.97.
• [51] Matsushita K,Hibi K,Komura N,et al. Impact of serum lipoprotein(a)level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome:a yokohama-acs substudy[J]. J Cardiol,2020,76(1):66-72. DOI:10.1016/j.jjcc.2020.01.005.
• [52] Kataoka S,Gohbara M,Iwahashi N,et al. Glycemic variability on continuous glucose monitoring system predicts rapid progression of non-culprit lesions in patients with acute coronary syndrome[J]. Circ J,2015,79(10):2246-2254. DOI:10.1253/circj.CJ-15-0496.
• [53] Wang J,Yan CY,Wang W,et al. The clinical prediction factors for non-culprit lesion progression in patients with acute ST elevation myocardial infarction after primary percutaneous coronary intervention[J]. BMC Cardiovasc Disord,2022,22(1):529. DOI:10.1186/s12872-022-02974-2.
• [54] Her AY,Cho KI,Singh GB,et al. Plaque characteristics and infiammatory markers for the prediction of major cardiovascular events in patients with ST-segment elevation myocardial infarction[J]. Int J Cardiovasc Imaging,2017,33(10):1445-1454. DOI:10.1007/s10554-017-1135-x.
• [55] Koyama K,Yoneyama K,Mitarai T,et al. Association between inflammatory biomarkers and thin-cap fibroatheroma detected by optical coherence tomography in patients with coronary heart disease[J]. Arch Med Sci,2015,11(3):505-512. DOI:10.5114/aoms.2015.52352.
• [56] Zhang TY,Zhao Q,Liu ZS,et al. Relationship between monocyte/lymphocyte ratio and non-culprit plaque vulnerability in patients with acute coronary syndrome:an optical coherence tomography study[J]. Medicine(Baltimore),2020,99(41):e21562. DOI:10.1097/MD.0000000000021562.
• [57] Liu T,Ji H,Jian X,et al. Novel nomogram for predicting coronary vulnerable plaque risk in patients with coronary artery disease[J].Biomark Med,2022,16(16):1139-1149. DOI:10.2217/bmm-2022-0855.
• [58]李楠，陈润真，颜红兵.急性心肌梗死循环标志物与罪犯斑块特点及其临床意义[J].中国介入心脏病学杂志，2022,30(3):214-218. DOI:10.3969/j.issn.1004-8812.2022.03.010.
• [59] Li T,Li X,Feng Y,et al. The role of matrix metalloproteinase-9in atherosclerotic plaque instability[J]. Mediators Inflamm,2020,2020:3872367. DOI:10.1155/2020/3872367.
• [60] Pouralijan AM,Khoshkam M,Salek RM,et al. Metabolomics in early detection and prognosis of acute coronary syndrome[J]. Clin Chim Acta,2019,495:43-53. DOI:10.1016/j.cca.2019.03.1632.
• [61]赵静雯，于海奕，张永珍，等.环状RNA circDYSF在不同类型冠心病患者外周血中的表达及临床价值探讨[J].中国介入心脏病学杂志，2022,30(11):801-807. DOI:10.3969/j.issn.1004-8812.2022.11.001.
• [62] Wald DS,Morris JK,Wald NJ,et al. Randomized trial of preventive angioplasty in myocardial infarction[J]. N Engl J Med,2013,369(12):1115-1123. DOI:10.1056/NEJMoa1305520.
• [63] Gershlick AH,Khan JN,Kelly DJ,et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease:the CvLPRIT trial[J]. J Am Coll Cardiol,2015,65(10):963-972. DOI:10.1016/j.jacc.2014.12.038.
• [64] Hlinomaz O,Groch L,Lehar F,et al. Multivessel coronary disease diagnosed at the time of primary PCI for STEMI:complete revascularization versus conservative strategy[C]. PRAGUE 13trial,Presented at:Euro PCR,Paris,France,2015.
• [65] Levine GN,Bates ER,Blankenship JC,et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction:an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction[J]. J Am Coll Cardiol,2016,67(10):1235-1250. DOI:10.1016/j.jacc.2015.10.005.
• [66] Mehta SR,Wood DA,Storey RF,et al. Complete revascularization with multivessel PCI for myocardial infarction[J].N Engl J Med,2019,381(15):1411-1421. DOI:10.1056/NEJMoa1907775.
• [67] Kornowski R,Mehran R,Dangas G,et al. Prognostic impact of staged versus “one-time” multivessel percutaneous intervention in acute myocardial infarction:analysis from the HORIZONSAMI(harmonizing outcomes with revascularization and stents in acute myocardial infarction)trial[J]. J Am Coll Cardiol,2011,58(7):704-711. DOI:10.1016/j.jacc.2011.02.071.
• [68] Tea V,Morelle JF,Gallet R,et al. Immediate versus staged complete myocardial revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease:a post hoc analysis of the randomized FLOWER-MI trial[J]. Arch Cardiovasc Dis,2022,115(10):496-504. DOI:10.1016/j.acvd.2022.05.011.
• [69] Dangas GD,George JC,Weintraub W,et al. Timing of staged percutaneous coronary intervention in multivessel coronary artery disease[J]. JACC Cardiovasc Interv,2010,3(10):1096-1099. DOI:10.1016/j.jcin.2010.09.005.
• [70] Chen D,Jepson N. Coronary stent technology:a narrative review[J]. Med J Aust,2016,205(6):277-281. DOI:10.5694/mja16.00444.
• [71] Bourantas CV,Serruys PW,Nakatani S,et al. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions:a concept based on serial optical coherence tomography data[J]. EuroIntervention,2015,11(7):746-756. DOI:10.4244/eijy14m10_06.
• [72] Stone GW,Maehara A,Ali ZA,et al. Percutaneous coronary intervention for vulnerable coronary atherosclerotic plaque[J].J Am Coll Cardiol,2020,76(20):2289-2301. DOI:10.1016/j.jacc.2020.09.547.
• [73] Her AY,Shin ES,Chung JH,et al. Plaque modification and stabilization after paclitaxel-coated balloon treatment for de novo coronary lesions[J]. Heart Vessels,2019,34(7):1113-1121. DOI:10.1007/s00380-019-01346-9.
• [74] Bonaca MP,Bhatt DL,Cohen M,et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med,2015,372(19):1791-1800. DOI:10.1056/NEJMoa1500857.
• [75] Case BC,Torguson R,Shea C,et al. Association of statins with nonculprit coronary lesions and adverse events(from the LRP study)[J]. Am J Cardiol,2023,190:82-89. DOI:10.1016/j.amjcard.2022.11.048.
• [76] Mach F,Baigent C,Catapano AL,et al. 2019 ESC/E A S Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J,2020,41(1):111-188. DOI:10.1093/eurheartj/ehz455.
• [77] Nicholls SJ,Puri R,Anderson T,et al. Ef fect of evolocumab on progression of coronary disease in statin-treated patients:the GLAGOV randomized clinical trial[J]. JAMA,2016,316(22):2373-2384. DOI:10.1001/jama.2016.16951.
• [78] Aimo A,Pascual-Figal DA,Barison A,et al. Colchicine for the treatment of coronary artery disease[J]. Trends Cardiovasc Med,2021,31(8):497-504. DOI:10.1016/j.tcm.2020.10.007.
• [79] Everett BM,MacFadyen JG,Thuren T,et al. Inhibition of interleukin-1beta and reduction in atherothrombotic cardiovascular events in the CANTOS trial[J]. J Am Coll Cardiol,2020,76(14):1660-1670. DOI:10.1016/j.jacc.2020.08.011.
• [80] Visseren FLJ,Mach F,Smulders YM,et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice:developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology(EAPC)[J]. Rev Esp Cardiol(Engl Ed),2022,75(5):429. DOI:10.1016/j.rec.2022.04.003.